TY - JOUR
T1 - Inhibitory mechanisms of YC-1 and PMC in the induction of iNOS expression by lipoteichoic acid in RAW 264.7 macrophages
AU - Hsiao, George
AU - Huang, Hsin Yi
AU - Fong, Tsorng Harn
AU - Shen, Ming Yi
AU - Lin, Chien Huang
AU - Teng, Chen Ming
AU - Sheu, Joen Rong
N1 - Funding Information:
This work was financially supported by a research grant from the National Science Council of Taiwan (NSC 89-2320-B-038-058).
PY - 2004/4/1
Y1 - 2004/4/1
N2 - In the present study, the signal pathways involved in NO formation and iNOS expression in RAW 264.7 macrophages stimulated by LTA were investigated. We also compared the relative inhibitory activities and mechanisms of PMC, a novel potent antioxidant of α-tocopherol derivatives, with those of YC-1, an sGC activator, on the induction of iNOS expression by LTA in cultured macrophages in vitro and LTA-induced hypotension in vivo. LTA induced concentration (0.1-50μg/mL)- and time (4-24hr)-dependent increases in nitrite (an indicator of NO biosynthesis) in macrophages. Both PMC (50μM) and YC-1 (10μM) inhibited NO production, iNOS protein, mRNA expression, and IκBα degradation upon stimulation by LTA (20μg/mL) in macrophages. On the other hand, PMC (50μM) almost completely suppressed JNK/SAPK activation, whereas YC-1 (10μM) only partially inhibited its activation in LTA-stimulated macrophages. Moreover, PMC (10mg/kg, i.v.) and YC-1 (5mg/kg, i.v.) significantly inhibited the fall in MAP stimulated by LTA (10mg/kg, i.v.) in rats. In conclusion, we demonstrate that YC-1 shows more-potent activity than PMC at abrogating the expression of iNOS in macrophages in vitro and reversing delayed hypotension in rats with endotoxic shock stimulated by LTA. The inhibitory mechanisms of PMC may be due to its antioxidative properties, with a resulting influence on JNK/SAPK and NF-κB activations. YC-1 may be mediated by increasing cyclic GMP, followed by, at least partly, inhibition of JNK/SAPK and NF-κB activations, thereby leading to inhibition of iNOS expression.
AB - In the present study, the signal pathways involved in NO formation and iNOS expression in RAW 264.7 macrophages stimulated by LTA were investigated. We also compared the relative inhibitory activities and mechanisms of PMC, a novel potent antioxidant of α-tocopherol derivatives, with those of YC-1, an sGC activator, on the induction of iNOS expression by LTA in cultured macrophages in vitro and LTA-induced hypotension in vivo. LTA induced concentration (0.1-50μg/mL)- and time (4-24hr)-dependent increases in nitrite (an indicator of NO biosynthesis) in macrophages. Both PMC (50μM) and YC-1 (10μM) inhibited NO production, iNOS protein, mRNA expression, and IκBα degradation upon stimulation by LTA (20μg/mL) in macrophages. On the other hand, PMC (50μM) almost completely suppressed JNK/SAPK activation, whereas YC-1 (10μM) only partially inhibited its activation in LTA-stimulated macrophages. Moreover, PMC (10mg/kg, i.v.) and YC-1 (5mg/kg, i.v.) significantly inhibited the fall in MAP stimulated by LTA (10mg/kg, i.v.) in rats. In conclusion, we demonstrate that YC-1 shows more-potent activity than PMC at abrogating the expression of iNOS in macrophages in vitro and reversing delayed hypotension in rats with endotoxic shock stimulated by LTA. The inhibitory mechanisms of PMC may be due to its antioxidative properties, with a resulting influence on JNK/SAPK and NF-κB activations. YC-1 may be mediated by increasing cyclic GMP, followed by, at least partly, inhibition of JNK/SAPK and NF-κB activations, thereby leading to inhibition of iNOS expression.
KW - BHA
KW - Butylated hydroxyanisole
KW - ERK
KW - Extracellular signal-regulated kinase
KW - IFN-γ
KW - INOS
KW - Inducible nitric oxide synthase
KW - Interferon-γ
KW - IκBα
KW - JAK/STAT
KW - LPS
KW - LTA
KW - Lipopolysaccharide
KW - Lipoteichoic acid
KW - NF-κB inhibitory protein
UR - http://www.scopus.com/inward/record.url?scp=1542375423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1542375423&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2003.12.010
DO - 10.1016/j.bcp.2003.12.010
M3 - Article
C2 - 15013857
AN - SCOPUS:1542375423
SN - 0006-2952
VL - 67
SP - 1411
EP - 1419
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 7
ER -